Tesamorelin for Visceral Fat: What the Clinical Data Shows
Most growth hormone peptides have thin evidence for fat loss. Tesamorelin is the exception, FDA-approved with real trial data measuring visceral fat reduction by CT imaging. Here is how the mechanism works, who fits the protocol, and what monitoring it requires.
GLP-1 Plateau at Month 6: What Actually Causes It
Weight loss on semaglutide or tirzepatide slows around month six, and the trial curves predicted it. The plateau is the body’s energy conservation response, not drug failure. Here is the physiology and the clinical levers that push through it.
Weight Regain After GLP-1 Medications: What the Clinical Data Actually Shows
The clinical data shows most people regain two-thirds of lost weight after stopping GLP-1 medications. Here’s why it happens and what actually prevents it.
GLP-1 Medications for Weight Loss: Semaglutide vs. Tirzepatide vs. Retatrutide
Confused about which GLP-1 medication is right for you? This guide compares semaglutide, tirzepatide, and retatrutide so you can make an informed choice.
